• Cellectis won FDA RMAT designation for lasme-cel in relapsed or refractory B-cell acute lymphoblastic leukemia.
• The CD22-targeting allogeneic CAR-T is in the open-enrollment pivotal Phase 2 portion of the BALLI-01 trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectis SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606091630PRIMZONEFULLFEED9734140) on June 09, 2026, and is solely responsible for the information contained therein.